Trending tickers: Pfizer, Micron, Nissan, Teva and National Grid [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Pharmaceuticals giant Pfizer closed Tuesday's session nearly 5% in the green, after it issued an upbeat full-year outlook for 2025. Pfizer guided to 2025 revenue of between $61bn (£48bn) and $64bn, along with adjusted earnings per share of $2.80 to $3 next year, both of which were in line with expectations. Read more: FTSE 100 LIVE: Markets higher as UK inflation bump points to Bank of England interest rate hold The drugmaker also reiterated its 2024 full-year guidance, estimating earnings per share of between $2.75 and $2.95. Pfizer said it had also delivered on its goal of $4bn in net operating expense savings through 2024, with a further $500m in savings expected to come in 2025. Dr. Albert Bourla, CEO of Pfizer, said: "Additionally, in support of our ongoing efforts to improve gross margin performance, we will work to make additional progress with our manufacturing optimization program in the coming year." NYSE Nasdaq Real Time Price • USD Pfizer Inc. (PFE) Fo
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire
- Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? [Yahoo! Finance]Yahoo! Finance
- Why Pfizer (PFE) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- GoComet's Odyssey Singapore 2024 Highlights: When Supply Chain Giants MeetPR Web
PFE
Earnings
- 10/29/24 - Beat
PFE
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 8-K
- PFE's page on the SEC website